Search

Displaying results 2511 - 2520 of 9325 in total
  1. Drug

    Lovotibeglogene autotemcel

    go.drugbank.com/drugs/DB18680
    ApprovedInvestigational

    12 years and older to be approved by the FDA. … [A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who

  2. Drug

    Vusolimogene oderparepvec

    go.drugbank.com/drugs/DB23008
    ApprovedInvestigational

    [L64061,L64062] It is the second oncolytic viral therapy approved in the United States, following talimogene laherparepvec (T-VEC, Imlygic) in 2015, and the first approved for melanoma that has progressed … [L64062,L64063] The approval came on the therapy's third submission, after two prior complete response letters.[L64063]

  3. Drug

    N-(2-Aminoethyl)-1-aziridineethanamine

    go.drugbank.com/drugs/DB15643
    Experimental

    First described in the literature in 2004, N-(2-Aminoethyl)-1-aziridineethanamine is an experimental angiotensin converting enzyme 2 inhibitor investigated for its use in treating cardiovascular disease

    Categories: Agents Acting on the Renin-Angiotensin System
  4. Drug

    Gallium nitrate

    go.drugbank.com/drugs/DB05260
    ApprovedInvestigational

    [A17097] GANITE, a product of gallium nitrate previously used to treat cancer-related hypercalcemia, was discontinued from marketing in the US for reasons other than safety or effectiveness. … [A260816] Gallium nitrate is reported to possess antiresorptive and hypocalcemic effects on bone.

  5. Drug

    Tucatinib

    go.drugbank.com/drugs/DB11652
    ApprovedInvestigational

    It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. … Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer.

  6. Drug

    Copanlisib

    go.drugbank.com/drugs/DB12483
    ApprovedInvestigational

    [A261730] Copanlisib was granted accelerated approval by the FDA in September 2017 for the treatment of follicular lymphoma.[A261725] … Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms.

  7. Drug

    Eugenol

    go.drugbank.com/drugs/DB09086
    ApprovedInvestigational

    Its exact mechanism of action is unknown, however, it has been shown to interfere with action potential conduction. … There are a number of unapproved OTC products available containing eugenol that advertise its use for the treatment of toothache.

  8. Drug

    Poractant alfa

    go.drugbank.com/drugs/DB09113
    ApprovedInvestigational

    The phospholipid content of the extract consists primarily of phosphatidylcholine and dipaImitoylphosphatidylcholine. … Poractant alfa is a pulmonary surfactant marketed as Curosurf in the United States and Canada.

  9. Drug

    Patiromer

    go.drugbank.com/drugs/DB09263
    ApprovedInvestigational

    Each gram of patiromer is equivalent to a nominal amount of 2 grams of patiromer sorbitex calcium. … Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015.

  10. Drug

    Medium-chain triglycerides

    go.drugbank.com/drugs/DB13959
    ApprovedInvestigational

    In the body, MCTs are broken down into glycerol and free fatty acids, which are directly absorbed into the blood stream and transported to the target organs to exert a range of biological and metabolic … Medium-chain triglycerides (MCTs) are triglycerides made up of a glycerol backbone and three fatty acids with an aliphatic tail of six to 12 carbon atoms.

    Mixtures: LIPOFUNDIN MCT/LCT %10 VIT E INFUZYON ICIN YAG EMULSUYONU, 100 ML, LIPOFUNDIN MCT/LCT %10 VIT E INFUZYON ICIN YAG EMULSUYONU, 250 ML